Literature DB >> 15894863

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus.

Toshihiko Inukai1, Noboru Yoshida, Sadao Wakabayashi, Yoshihisa Inukai, Rika Matsutomo, Keishi Takanashi, Takashi Nakamachi, Kohzo Takebayashi, Yoshimasa Aso, Kiyoko Takahashi.   

Abstract

BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) have potent antioxidant effects in addition to antihypertensive effects.
METHODS: We investigated the ability of ACEIs and ARBs to enhance the superoxide scavenging ability of polymorphonuclear leukocytes (PMNLs) from type 2 diabetic patients (n = 32) and healthy subjects (n = 32). The scavenging ability (U/10(3) cells) of superoxide was measured by electron spin resonance. We used ascorbic acid as a positive control antioxidant and tested captopril, temocapril (an inactive form of ACEI), and temocaprilate (an active form of ACEI) as ACEIs, as well as RNH-6270 as an ARB.
RESULTS: Captopril, temocaprilate, and RNH-6270 showed dose-dependent enhancement in scavenging ability. The scavenging ability with captopril and temocaprilate was greater than with RNH-6270. The changes in scavenging ability induced by all of the drugs in diabetic patients were similar to the changes in healthy subjects. A high-glucose medium (400-800 mg/dL) greatly attenuated the drug-induced enhancement of scavenging ability.
CONCLUSIONS: We demonstrated that both ACEIs and ARBs enhance superoxide scavenging by PMNLs from type 2 diabetic patients and that a high-glucose environment markedly attenuates the ability of these drugs to augment superoxide scavenging.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894863     DOI: 10.1097/00000441-200505000-00002

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

Review 1.  Olmesartan medoxomil: a review of its use in the management of hypertension.

Authors:  Lesley J Scott; Paul L McCormack
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity.

Authors:  Ariela Benigni; Silvia Orisio; Marina Noris; Paraskevas Iatropoulos; Davide Castaldi; Kei Kamide; Hiromi Rakugi; Yasumichi Arai; Marta Todeschini; Giulia Ogliari; Enyu Imai; Yasuyuki Gondo; Nobuyoshi Hirose; Daniela Mari; Giuseppe Remuzzi
Journal:  Age (Dordr)       Date:  2012-05-09

Review 3.  Pathophysiology, prevention and management of chronic kidney disease in the hypertensive patient with diabetes mellitus.

Authors:  Anna Solini; Ele Ferrannini
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-04       Impact factor: 3.738

Review 4.  The pleiotropic effects of angiotensin receptor blockers.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-04       Impact factor: 3.738

Review 5.  The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.

Authors:  Fabrizio Montecucco; Aldo Pende; François Mach
Journal:  Mediators Inflamm       Date:  2009-04-14       Impact factor: 4.711

Review 6.  A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity.

Authors:  Rebecca Dowey; Ahmed Iqbal; Simon R Heller; Ian Sabroe; Lynne R Prince
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.